Premium
Retinoblastoma associated binding protein 46: a potential prognostic marker for distal metastasis in non‐small cell lung cancer
Author(s) -
Wang ChihLiang,
Wang ChunI,
Liao PaoChi,
Liang Ying,
Wu ChihChing,
Chuang WenYu,
Tsai YingHuang,
Chen HuaChien,
Yu JauSong,
Yu ChiaJung
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.861.1
Subject(s) - lung cancer , biomarker , pathology , metastasis , medicine , lung , cancer , adenocarcinoma , cancer research , immunohistochemistry , chemistry , biochemistry
Previously, RbAp46 was identified as a novel body fluid protein from malignant plural effusions of lung adenocarcinoma by proteomic approach. In this report, we study the clinicopathologic significance of RbAp46 in non‐small cell lung cancer (NSCLC) and validate its application to be prognostic serum biomarker. We found RbAp46 mRNA was up‐regulated significantly in lung cancer tissues comparing to those in normal tissues. Strong nuclear stain of RbAp46 was observed in 75.3 % of lung cancer cells and 3.2 % of adjacent normal cells. RbAp46 was secreted from lung cancer cell lines and detected in conditioned media. Serum levels of RbAp46 were significantly higher in lung cancer patients versus healthy controls. The combination of serum RbAp46 and CEA levels could outperform CEA alone in discriminating patients from healthy controls in this case‐control study. Moreover, serum RbAp46 levels were positively correlated with distal metastasis of NSCLC. The migration ability of NSCLC cell line could be significantly inhibited by RbAp46 knockdown. Our studies suggest RbAp46 may be a novel biomarker and prognosticator for NSCLC and is involved in migration of lung cancer cells.